Nestle To Help Bring Microbiome Therapeutic Products To Market

Nestlé announced it would participate in commercialization efforts for the Ecobiotics line of microbiome drugs being tested in clinical trials by Seres Therapeutics. Nestlé Health Science has purchased an equity stake in Seres (Cambridge, Mass.), which is developing the microbiome products for the treatment of Clostridium difficile bacterial infections of the digestive system, and for inflammatory bowel disease. The various products, based on microbial organisms, target the 100 trillion microorganisms that live within the human body. They are in different phases of human testing. C. diff infections are most common in people 65 years and older, and in immune-compromised patients treated with antibiotics for underlying infections.